Somewhat Positive Press Coverage Somewhat Unlikely to Affect VistaGen Therapeutics (NASDAQ:VTGN) Stock Price

News stories about VistaGen Therapeutics (NASDAQ:VTGN) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VistaGen Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8295582517061 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of VistaGen Therapeutics (NASDAQ:VTGN) traded up $0.02 on Friday, hitting $1.22. The company’s stock had a trading volume of 873,500 shares, compared to its average volume of 1,686,813. The company has a debt-to-equity ratio of -0.01, a quick ratio of 1.23 and a current ratio of 1.23. VistaGen Therapeutics has a 52-week low of $0.69 and a 52-week high of $3.90. The company has a market capitalization of $25.78, a price-to-earnings ratio of -0.82 and a beta of -1.23.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, November 9th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). equities analysts forecast that VistaGen Therapeutics will post -1.99 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect VistaGen Therapeutics (NASDAQ:VTGN) Stock Price” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).

Insider Buying and Selling by Quarter for VistaGen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply